Teva snares up to $150M in Abingworth funding to propel late-stage asthma rescue inhaler

Shortly after Gilead Sciences teamed up with Carlyle’s Abingworth to fuel further research on its antibody-drug conjugate Trodelvy, Teva is following a similar pathway with an asthma rescue inhaler.

Monday, Teva and Abingworth revealed that they have entered a clinical collaboration agreement to advance TEV-’248, a dual-action combination of an inhaled corticosteroid and a short-acting beta-agonist (ICS/SABA). In a release, the companies said the prospect could become the first ICS/SABA for both the adult and pediatric patient population.